GE HealthCare Technologies (NASDAQ:GEHC) Stock Price Expected to Rise, UBS Group Analyst Says

GE HealthCare Technologies (NASDAQ:GEHC) had its target price hoisted by UBS Group from $67.00 to $73.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price target would indicate a potential upside of 7.32% from the company’s current price.

GEHC has been the topic of several other research reports. Mizuho cut their price objective on GE HealthCare Technologies from $90.00 to $80.00 in a report on Thursday, April 30th. Argus dropped their target price on GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Weiss Ratings lowered GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. BNP Paribas Exane reduced their price target on GE HealthCare Technologies from $95.00 to $88.00 in a report on Friday, May 1st. Finally, Rothschild & Co Redburn reduced their price target on GE HealthCare Technologies from $110.00 to $98.00 in a report on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GE HealthCare Technologies currently has an average rating of “Hold” and an average price target of $77.73.

GE HealthCare Technologies Price Performance

GEHC stock traded down $1.92 during trading on Friday, reaching $68.02. 5,126,733 shares of the company were exchanged, compared to its average volume of 4,611,242. The company has a market capitalization of $30.94 billion, a price-to-earnings ratio of 15.60, a P/E/G ratio of 1.96 and a beta of 0.72. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.26 and a quick ratio of 0.95. The company has a 50-day moving average of $63.94 and a two-hundred day moving average of $70.57. GE HealthCare Technologies has a twelve month low of $58.75 and a twelve month high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.26 billion. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $1.06 earnings per share. As a group, equities analysts predict that GE HealthCare Technologies will post 4.89 earnings per share for the current fiscal year.

Insider Activity at GE HealthCare Technologies

In related news, Director Kevin Lobo bought 10,000 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were purchased at an average cost of $64.18 per share, with a total value of $641,800.00. Following the acquisition, the director owned 14,363 shares of the company’s stock, valued at $921,817.34. This represents a 229.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Watkin Phoebe L. Yang purchased 1,000 shares of GE HealthCare Technologies stock in a transaction on Friday, May 8th. The stock was bought at an average price of $63.01 per share, for a total transaction of $63,010.00. Following the transaction, the director directly owned 13,702 shares in the company, valued at approximately $863,363.02. The trade was a 7.87% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 12,618 shares of company stock worth $805,175 over the last three months. Company insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On GE HealthCare Technologies

A number of institutional investors have recently modified their holdings of the company. Banque Cantonale Vaudoise lifted its stake in shares of GE HealthCare Technologies by 16,539.1% in the 1st quarter. Banque Cantonale Vaudoise now owns 25,957 shares of the company’s stock valued at $1,849,000 after purchasing an additional 25,801 shares during the period. Allstate Corp boosted its position in shares of GE HealthCare Technologies by 100.3% during the 4th quarter. Allstate Corp now owns 32,688 shares of the company’s stock valued at $2,681,000 after purchasing an additional 16,365 shares in the last quarter. Perpetual Ltd acquired a new stake in GE HealthCare Technologies during the fourth quarter worth approximately $37,656,000. Auto Owners Insurance Co grew its stake in GE HealthCare Technologies by 9,525.4% during the fourth quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after purchasing an additional 33,629,559 shares during the period. Finally, PFA Pension Forsikringsaktieselskab bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth approximately $43,394,000. 82.06% of the stock is owned by institutional investors.

GE HealthCare Technologies News Roundup

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
• Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
• Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
• Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.